98%
921
2 minutes
20
Focal epilepsy is the most common subtype of epilepsies in which the influence of underlying genetic factors is emerging but remains largely uncharacterized. The purpose of this study is to determine the contribution of currently known disease-causing genes in a large cohort ( = 593) of common focal non-lesional epilepsy patients. The customized focal epilepsy gene panel (21 genes) was based on multiplex polymerase chain reaction (PCR) and sequenced by Illumina MiSeq platform. Eleven variants (1.85%) were considered as pathogenic or likely pathogenic, including seven novel mutations. There were three (p.Leu890Pro, p.Arg1636Ter, and p.Met1714Val), three (two p.Arg217Profs8 and p.Leu298Pro), two (p.Ser284Leu, p.Ile321Asn), one (p.Val516Ter) (p.Asp233Asn), and one (p.Ser414Ter) variants. Additionally, 16 other rare variants were classified as unknown significance due to inconsistent phenotype or lack of segregation data. Currently known focal epilepsy genes only explained a very small subset of focal epilepsy patients. This indicates that the underlying genetic architecture of focal epilepsies is very heterogeneous and more novel genes are likely to be discovered. Our study highlights the usefulness, challenges and limitations of using the multi-gene panel as a diagnostic test in routine clinical practice in patients with focal epilepsy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043663 | PMC |
http://dx.doi.org/10.3389/fneur.2018.00515 | DOI Listing |
Epilepsy Res
September 2025
Medical Affairs, Torrent Pharmaceuticals Ltd, Ahmedabad 380009, India. Electronic address:
Objective: Primary generalized tonic-clonic seizures (pGTCS) are often misdiagnosed and remain challenging to manage due to limited treatment options. Lacosamide (LCM), approved for focal-onset seizures and adjunctive pGTCS therapy, was evaluated for real-world effectiveness in Indian patients.
Methods: This real-world, multicenter, retrospective, observational, and non-interventional study was conducted across 124 centers in India following approval from a centralized institutional ethics committee.
Epileptic Disord
September 2025
APHM, Timone Hospital, Epileptology and Cerebral Rhythmology, Marseille, France.
This case study reports the first documented use of stereoelectroencephalography (SEEG)-guided radiofrequency thermocoagulation (RFTC) to treat refractory status epilepticus (RSE). A 33-year-old woman with drug-resistant epilepsy and recurrent RSE underwent SEEG to define her epileptogenic zone. A new RSE started shortly before and continued during the SEEG exploration, being unresponsive to multiple antiseizure medications, vagal nerve stimulation, and corticosteroid therapy.
View Article and Find Full Text PDFBiomed Rep
November 2025
Department of Pediatric Neurology, King Fahad Specialist Hospital, Dammam 31444, Saudi Arabia.
Intraoperative electrocorticography (ECoG) represents a crucial tool for improving seizure outcomes during epilepsy surgeries by assisting in localization of the epileptogenic zones. There is a shortage of information in the literature regarding single-center experiences and long-term outcomes after ECoG-guided surgeries. Data are particularly scarce from the Eastern Mediterranean Region.
View Article and Find Full Text PDFAlpha Psychiatry
August 2025
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 130021 Changchun, Jilin, China.
Background: The progressive legalization and widespread use of cannabis has led to its use as a treatment for certain neuropsychiatric disorders. Traditional epidemiological studies suggest that cannabis use has an effect on some neurocognitive aspects. However, it is unclear whether cannabis use is causally related to common neuropsychiatric disorders.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, "Dr. Bernardo Sepúlveda", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
Background: Cannabidiol (CBD) reduces the frequency of seizures in individuals with specific epileptic syndromes, but its effectiveness for other types of drug-resistant epilepsy (DRE) is unclear. CYP450 enzymes primarily metabolize CBD. The aim of this study was to identify CYP450 genotypes regarding the response of CBD treatment concomitant with anti-seizure drugs in patients with DRE.
View Article and Find Full Text PDF